Investigating the knowledge, attitude, and practice of cranberry extract supplements among registered pharmacists in Jordan Authors: Laith Al-Shdifat, Shaymaa B. Abdulrazzaq, Samar Thiab, Razan I. Nassar, Mais Ziwana, Ala’a Abu-Zaid, Mohammed Alostath, Dana R. Jarrar, Muna Barakat, Diana Malaeb Published: 2026 ABSTRACT American cranberry (Vaccinium macrocarpon) is consumed as juice, fruit, or standardized supplements and is widely promoted for urinary tract health. Evidence suggests cranberry preparations may help prevent urinary tract infections (UTIs), yet pharmacists’ knowledge and counseling practices may vary. This study assessed knowledge, attitudes, and practices (KAP) regarding cranberry extract among registered pharmacists in Jordan. A self-administered online questionnaire, developed from the literature and assessed for face/content validity and internal consistency, was distributed to registered pharmacists in Jordan. Knowledge was assessed using 14 true/false/I do not know items, while attitudes and practices were assessed using Likert-type scales. Descriptive analyses were supplemented with bivariate testing, multivariable regression models, correlation analyses, and a comparison of participants who did and did not complete the practice section. A total of 409 responses were analyzed. Participants were predominantly aged < = 35 years (82.6%), resided in central Jordan (89.2%), and worked in community pharmacies (52.6%). Overall knowledge was moderate/neutral (mean 7.65 ± 3.07 out of 14), and 57.9% had low knowledge scores using Bloom’s < 60% cut-off. Attitudes were neutral overall (mean 3.21 ± 0.41 out of 5). Among 268 participants who completed the practice section, the mean practice score was 3.14 ± 0.70 out of 5. In multivariable analysis, working in community pharmacy (β = 1.16, 95% CI 0.53 to 1.79; p < 0.001) and using research/books/university sources of information (β = 1.18, 95% CI 0.43 to 1.92; p = 0.002) independently predicted higher knowledge. Among practice-section respondents, higher knowledge (β = 0.05, 95% CI 0.02 to 0.08; p < 0.001) and more positive attitudes (β = 0.44, 95% CI 0.26 to 0.63; p < 0.001) independently predicted safer practice scores. Jordanian pharmacists recognized cranberry’s role in UTI prevention, but clinically relevant gaps were identified regarding safety, interactions, dose limits, pregnancy/lactation uncertainty, and appropriate counselling. The inferential analyses suggest that evidence-based information sources and KAP interrelationships are important targets for continuing professional development. Findings should be interpreted cautiously because recruitment was online and the practice section was completed mainly by pharmacists for whom cranberry dispensing was applicable. Introduction Cranberry (Vaccinium macrocarpon Ait.), an evergreen shrub native to North America, is recognised for its high content of bioactive phytochemicals, including proanthocyanidins (PACs), anthocyanins, flavonols, and phenolic acids1. These compounds confer antioxidant, anti-inflammatory, antibacterial, and anti-adhesive properties2. Historically, the native American sailors consumed cranberries during their ocean trips to prevent scurvy3. Recently, the reported health benefits of cranberry consumption range from cardioprotective effects due to improved cholesterol profiles5 to aiding in digestive health2. Cranberries may also have possible effects on metabolic syndrome, oral health, cancer prevention, and immune modulation6. Some studies have investigated their potential use as a neutral food preservative, a source of bioactive compounds, and a functional ingredient in dietary products7. Supplements containing cranberry extract are frequently marketed as a non-antibiotic option to avoid recurrent urinary tract infections (UTIs), which are a prevalent ailment in the Middle East and North Africa, including Jordan7,8. Cranberry products are consumed in various forms (juice, capsules, tablets, dried fruit, and sauces)6 the proposed mechanism involves type-A proanthocyanidins that inhibit P-fimbriated Escherichia coli adhesion to uroepithelial cells9. Several Cochrane reviews and meta-analyses have yielded conflicting conclusions regarding the clinical efficacy of cranberry extracts, highlighting moderate evidence for UTIs10–12. Cranberry extracts were found to be among the complementary and alternative medicine products used in Jordan for urinary tract illnesses13. Pharmacists have a crucial role to ensure the safe, evidence-based use of these supplements; however, they often report limited knowledge, training gaps, and regulatory uncertainty for dietary and herbal products14,15. To date, no published study has specifically examined Jordanian pharmacists’ knowledge, attitudes, and practices regarding cranberry extract supplementation. Evidence from other countries suggests that improving pharmacists’ knowledge can enhance attitudes and, in turn, counselling practice for dietary supplements16–18. Therefore, the present study aimed to comprehensively assess the knowledge, attitudes, and dispensing practices of registered pharmacists in Jordan regarding cranberry extract. Understanding how these domains interrelate for cranberry products among Jordanian pharmacists is crucial to design targeted educational and policy interventions that support safe and effective use of these products. Methodology Study design and participants A self-administered questionnaire was developed using Google Forms. The questionnaire was designed and administered in English because pharmacy education and most professional drug-information references in Jordan are commonly delivered in English. To reduce the possibility of misunderstanding, the English version was reviewed for clarity during face/content validation and pilot testing before full distribution. Nevertheless, because English is not the native language of all respondents, possible language-related misinterpretation is acknowledged as a limitation. The survey link was circulated through professional and social-media platforms, including Facebook, Instagram, X, WhatsApp, and LinkedIn. Because the survey was distributed online and anonymously, duplicate submission was completely excluded as respondents were restricted through the Google Forms “limit to one response” setting. The inclusion criteria, displayed before informed consent, required participants to confirm that they were registered pharmacists practicing or residing in Jordan. Participants who did not provide consent were not allowed to proceed to the survey. Practice items were interpreted as self-reported dispensing or counselling behaviour among respondents for whom cranberry dispensing was applicable; for pharmacists outside direct dispensing settings, practice responses may reflect perceived or hypothetical behaviour rather than observed routine practice. Sample size The sample size was estimated using Open-Source Epidemiologic Statistics for Public Health (OpenEpi), version 3.01, assuming a 95% confidence level, a 5% margin of error, and a conservative expected proportion of 50%. The Jordan Pharmacists Association currently lists 37,088 pharmacists in Jordan20. Using this large target population, the minimum required sample was approximately 380–385 pharmacists; therefore, the final analytical sample of 409 respondents exceeded the minimum required sample size. Questionnaire development, validation, and reliability Following an extensive review of previously published KAP and dietary-supplement surveys18–23, the questionnaire was developed in line with published survey-design guidance24. Because no cranberry-specific validated questionnaire for pharmacists was available, items were generated to match the study objectives and the available evidence on cranberry use, safety, interactions, and counselling. The questionnaire was assessed for face and content validity by five academics with relevant expertise. A pilot test was then conducted with 20 participants to evaluate item clarity, language comprehension, and completion flow; pilot responses were excluded from the final analysis. Internal consistency was acceptable for the Likert-type sections (Cronbach’s alpha = 0.79 for attitude and 0.81 for practice). Therefore, the instrument should be described as literature-informed and assessed for face/content validity and internal consistency, rather than as a fully construct-validated questionnaire. The questionnaire comprised four sections: sociodemographic characteristics; knowledge of cranberry extract; attitudes toward cranberry extract; and dispensing/counselling practices. Knowledge items assessed evidence-based use in UTI prevention, potential interactions with anticoagulant/antiplatelet medicines, dose and administration considerations, safety uncertainty in pregnancy/lactation, and adverse effects such as gastrointestinal upset and kidney-stone risk. The attitude section assessed views regarding prevention versus treatment, standardised pharmaceutical products versus crude herbal preparations, online marketing, and substitution for antibiotics. The practice section assessed self-reported counselling and dispensing patterns, including patient screening, concomitant antibiotic use, patient groups, and dosage forms. Score calculation Knowledge scores were calculated by assigning 1 point for each correct answer and 0 points for incorrect or “I do not know” answers; reverse-coded items were scored accordingly. In addition to the total knowledge score, “I do not know” responses and incorrect responses were reported separately to distinguish uncertainty from misconceptions. Attitude items were scored from 1 to 5, with negatively worded items reverse-coded so that higher scores reflected more evidence-based attitudes. Practice items used a frequency scale (always, often, sometimes, rarely, never), with unsafe-practice items reverse-coded so that higher scores reflected safer practice. Bloom’s cut-off points were applied as follows: <60% indicated low knowledge/negative attitude/poor practice, 60–79% indicated moderate or neutral levels, and > = 80% indicated high knowledge/positive attitude/good practice. Ethical approval The study was approved by the Institutional/Local Research Ethics Committee, Amman, Jordan (Approval number: 2024-PHA-4). All participants agreed to participate in the study by selecting “I agree” on the electronic informed consent form before filling out the questionnaire. All methods were performed in accordance with the relevant guidelines and regulations or declaration of Helsinki. Statistical analysis Data were analyzed using Python 3.11 with SciPy and stats-models. Categorical variables were summarized as frequencies and percentages, while continuous KAP scores were summarized as means and standard deviations. Bivariate analyses used chi-square tests for categorical variables, independent-samples t-tests for two-group comparisons of continuous scores, and Pearson correlation coefficients to examine relationships among knowledge, attitude, and practice scores. Multivariable linear regression was used to identify independent predictors of knowledge score and practice score, and binary logistic regression was used to identify predictors of low knowledge (< 60% of the total score; <=8/14) and practice-section completion. Regression models included theoretically relevant demographic and professional variables, including age, gender, postgraduate education, work sector, experience, region, and information source. Heteroscedasticity-robust standard errors were used for linear regression. Statistical significance was set at p < 0.05. Results A total of 409 participants completed the study’s survey. The largest proportion of the participants was between 25 and 30 years old (42.5%), followed by 30.3% being less than 25 years old. The distribution of the gender was almost equal among the study’s participants, with 50.6% of them being females (n = 207). Approximately, 70.4% (n = 288) were single. Most of the participants held at least a bachelor’s degree (80.9%). Similarly, the majority were residing in the central regions of Jordan (89.2%). Regarding the work sector, more than half of the participants were working in a community pharmacy (n = 215). In addition, 46.7% (n = 191) reported having from one to five experience years. Financial status showed that more than one-third of the participants (n = 151, 36.9%) had a monthly income of 260–500 JD, and this was followed by about one-quarter of the participants (n = 106, 25.9%) reporting an income of 501–750 JD per month. Furthermore, 70.2% of the participants (n = 287) had health insurance, while 29.8% were uninsured (Table 1). Table 1Sociodemographic characteristics of the participants (n = 409).Variable n %Age (in years)Less than 2512430.325–3017442.530–35409.835–40266.441–50358.6More than 50102.4GenderMale20249.4Female20750.6Marital statusSingle28870.4Married11227.4Divorced71.7Widowed20.5Education levelDiploma276.6Bachelor’s degree33180.9Postgraduate degree (Master’s degree or PhD)5112.5Living placeNorth region (Irbid, Ajloun, Jerash, Mafraq)327.8Central region (Amman, Zarqa, Balqa, Madaba)36589.2South region (Karak, Tafilah, Ma‘an, Aqaba)122.9Work sectorCommunity pharmacy21552.6Hospital pharmacy163.9Medical representative7919.3Academic409.8Others5914.4Work experience< 1 year9924.21–5 years19146.76–10 years6215.211–15 years338.116–20 years122.9> 20 years122.9Monthly income in Jordanian DinarLess than 260 JD/month5513.4260–500 JD/month15136.9501–750 JD/month10625.9751–1000 JD/month5212.7More than 1000 JD/month4511.0Insurance statusInsured28770.2Uninsured12229.8 Table 1Sociodemographic characteristics of the participants (n = 409).Variable n %Age (in years)Less than 2512430.325–3017442.530–35409.835–40266.441–50358.6More than 50102.4GenderMale20249.4Female20750.6Marital statusSingle28870.4Married11227.4Divorced71.7Widowed20.5Education levelDiploma276.6Bachelor’s degree33180.9Postgraduate degree (Master’s degree or PhD)5112.5Living placeNorth region (Irbid, Ajloun, Jerash, Mafraq)327.8Central region (Amman, Zarqa, Balqa, Madaba)36589.2South region (Karak, Tafilah, Ma‘an, Aqaba)122.9Work sectorCommunity pharmacy21552.6Hospital pharmacy163.9Medical representative7919.3Academic409.8Others5914.4Work experience< 1 year9924.21–5 years19146.76–10 years6215.211–15 years338.116–20 years122.9> 20 years122.9Monthly income in Jordanian DinarLess than 260 JD/month5513.4260–500 JD/month15136.9501–750 JD/month10625.9751–1000 JD/month5212.7More than 1000 JD/month4511.0Insurance statusInsured28770.2Uninsured12229.8 Sociodemographic characteristics of the participants (n = 409). The study’s participants were asked about their primary source of information about cranberry (Fig. 1). The most reported source of information was the internet and social media (n = 129, 31.54%). Additionally, slightly less than one-fifth of the participants indicated that they depend on doctors and specialists (n = 74, 18.09%). A close proportion of the participants (17.36%) reported that they depend on their personal experiences (n = 71). The least reported source among the participants was family and friends (n = 28, 6.86%) (Fig. 2). Fig. 1Participants’ main source of information about cranberry extract (n = 409). Participants’ main source of information about cranberry extract (n = 409). Among respondents who completed the practice-related items (n = 268), the most commonly reported cranberry forms dispensed were sachets (219/268, 81.7%), capsules (217/268, 81.0%), and tablets (187/268, 69.8%). Syrup was reported by 121/268 (45.1%), while topical cranberry products were reported by only 32/268 (11.9%). Fig. 2Cranberry product forms reported as dispensed by practice-section respondents (n = 268). Cranberry product forms reported as dispensed by practice-section respondents (n = 268). The mean knowledge score was 7.65 ± 3.07 out of 14, indicating an overall moderate/neutral level of knowledge. Using Bloom’s < 60% cut-off, 237 participants (57.9%) had low knowledge scores ( < = 8/14). Table 2 reports correct, incorrect, and “I do not know” responses separately. The highest correct response was observed for cranberry use in UTI prevention (368/409, 90.0%). However, several clinically important gaps remained: only 163/409 (39.9%) correctly rejected the statement that there is no anticoagulant interaction risk with moderate cranberry intake, 189/409 (46.2%) recognized bleeding-risk concerns with excessive intake, and 201/409 (49.1%) recognized oxalate-stone risk in predisposed nephrolithiasis patients. Only 115/409 (28.1%) correctly rejected the overgeneralized statement that cranberry extract is safe for pregnant and lactating women at any dose. Table 2Participants’ knowledge responses regarding cranberry extract (n = 409), with separate reporting of correct, incorrect, and “I do not know” responses.ItemCorrect answerCorrect n (%)Incorrect n (%)I do not know n (%)1. Safe dose of cranberry dietary supplement is < 1350 mg/dayTrue229 (56.0)39 (9.5)141 (34.5)2. Cranberry extract is commonly used to prevent UTIsTrue368 (90.0)29 (7.1)12 (2.9)3. Cranberry extract can suppress H. pylori infectionsTrue196 (47.9)101 (24.7)112 (27.4)4. There is no risk of anticoagulant interaction with moderate cranberry intake*False163 (39.9)138 (33.7)108 (26.4)5. Cranberry products used for UTI prevention are administered orallyTrue306 (74.8)64 (15.6)39 (9.5)6. Cranberries contain salicylic acid and excessive intake may increase bleeding riskTrue189 (46.2)74 (18.1)146 (35.7)7. High doses are contraindicated/cautioned in history of kidney disease or stonesTrue234 (57.2)68 (16.6)107 (26.2)8. Cranberry extract is safe for pregnant/lactating women at any dose*False115 (28.1)205 (50.1)89 (21.8)9. Cranberry extract may help prevent dental infectionsTrue161 (39.4)99 (24.2)149 (36.4)10. Gastrointestinal upset is a possible adverse effectTrue249 (60.9)83 (20.3)77 (18.8)11. Diarrhea is a possible adverse effectTrue219 (53.5)99 (24.2)91 (22.2)12. Increased cancer risk is a cranberry adverse effect*False266 (65.0)49 (12.0)94 (23.0)13. Kidney stones may occur with high-dose cranberry intakeTrue233 (57.0)83 (20.3)93 (22.7)14. Oxalate stones may increase in predisposed nephrolithiasis patientsTrue201 (49.1)80 (19.6)128 (31.3)Total knowledge score, mean ± SD7.65 ± 3.07/14*Reverse-coded item. Incorrect answers and “I do not know” responses are shown separately to distinguish misconceptions from uncertainty. Table 2Participants’ knowledge responses regarding cranberry extract (n = 409), with separate reporting of correct, incorrect, and “I do not know” responses.ItemCorrect answerCorrect n (%)Incorrect n (%)I do not know n (%)1. Safe dose of cranberry dietary supplement is < 1350 mg/dayTrue229 (56.0)39 (9.5)141 (34.5)2. Cranberry extract is commonly used to prevent UTIsTrue368 (90.0)29 (7.1)12 (2.9)3. Cranberry extract can suppress H. pylori infectionsTrue196 (47.9)101 (24.7)112 (27.4)4. There is no risk of anticoagulant interaction with moderate cranberry intake*False163 (39.9)138 (33.7)108 (26.4)5. Cranberry products used for UTI prevention are administered orallyTrue306 (74.8)64 (15.6)39 (9.5)6. Cranberries contain salicylic acid and excessive intake may increase bleeding riskTrue189 (46.2)74 (18.1)146 (35.7)7. High doses are contraindicated/cautioned in history of kidney disease or stonesTrue234 (57.2)68 (16.6)107 (26.2)8. Cranberry extract is safe for pregnant/lactating women at any dose*False115 (28.1)205 (50.1)89 (21.8)9. Cranberry extract may help prevent dental infectionsTrue161 (39.4)99 (24.2)149 (36.4)10. Gastrointestinal upset is a possible adverse effectTrue249 (60.9)83 (20.3)77 (18.8)11. Diarrhea is a possible adverse effectTrue219 (53.5)99 (24.2)91 (22.2)12. Increased cancer risk is a cranberry adverse effect*False266 (65.0)49 (12.0)94 (23.0)13. Kidney stones may occur with high-dose cranberry intakeTrue233 (57.0)83 (20.3)93 (22.7)14. Oxalate stones may increase in predisposed nephrolithiasis patientsTrue201 (49.1)80 (19.6)128 (31.3)Total knowledge score, mean ± SD7.65 ± 3.07/14*Reverse-coded item. Incorrect answers and “I do not know” responses are shown separately to distinguish misconceptions from uncertainty. Participants’ knowledge responses regarding cranberry extract (n = 409), with separate reporting of correct, incorrect, and “I do not know” responses. *Reverse-coded item. Incorrect answers and “I do not know” responses are shown separately to distinguish misconceptions from uncertainty. Evaluating the study’s participants’ attitudes toward Cranberry extracts showed different attitudes (Table 3). According to two items (2 and 6), the participants had a positive attitude. Three items (3, 4, and 7) indicated that the participants had a neutral attitude, and three items (1, 5, and 8) revealed negative attitude. The positive attitude was revealed after 81.6% of the participants strongly agreed/agreed that there is a difference between herbs and pharmaceutical form, and 77.5% strongly agreed/agreed that there is need to regulate electronic trading of cranberry extract (Table 3). Regarding the neutral attitude, it was revealed after 64.5% strongly agreed/agreed that beneficial superiority of pharmaceutical formulation over the crude herb extract, 66.7% strongly agreed/agreed that cranberry extract is not a treatment for UTIs but only effective as a prophylaxis, and 26.6% strongly agreed/agreed with incorrect statement (reversed score) that supporting use cranberry extract instead of antibiotics to treat infections, (items 4,7 and 3), respectively (Table 3). The negative attitude was revealed after 57.0% strongly agreed/agreed that during infection treatment it is safer to use cranberry extract rather than antibiotics, 73.1% strongly agreed/agreed that it is safe to use cranberry extract frequently, and 80.2% of the participants strongly agreed/agreed that cranberry extract can be considered as treatment option for urinary tract infection, (items 5,8 and 1, respectively) (Table 3). Table 3Participants’ attitude toward Cranberry extracts (n = 409).Statementsn (%)Mean±SDStrongly agreeAgreeNeutralfStrongly disagree1. Cranberry extract is effective as a treatment option for recurrent urinary tract infection*222 (54.3)106 (25.9)43 (10.5)22 (5.4)16 (3.9)1.81.082. There is a difference between the pharmaceutical forms and herbs183 (44.7)151 (36.9)58 (14.2)11 (2.7)6 (1.5)4.20.893. Cranberry extract can replace the antibiotics in treatment of infections*48 (11.7)61 (14.9)72 (17.6)119 (29.1)109 (26.7)3.41.344. Pharmaceutical formulations are more beneficial than the crude herbal extract151 (36.9)113 (27.6)110 (26.9)28 (6.8)7 (1.7)3.91.035. Cranberry extract is safer than antibiotics for treatment of infections*128 (31.1)106 (25.9)113 (27.6)44 (10.8)18 (4.4)2.31.156. I believe that online selling of cranberry extract needs more monitoring211 (51.6)106 (25.9)66 (16.1)14 (3.4)12 (2.9)4.21.027. Cranberry extract is only effective as a prevention of recurrent urinary tract infection and not as a treatment option151 (36.9)122 (29.8)69 (16.9)53 (13.0)14 (3.4)3.81.168. In general, cranberry extracts are safe to be used frequently*155 (37.9)144 (35.2)83 (20.3)17 (4.2)10 (2.4)2.00.98MeanSDAttitude score**3.21± 0.41*These statements are reverse coded (Strongly disagree: 5, Disagree: 4, Neutral: 3, Agree: 2, Strongly agree: 1).**Attitude Score (mean ± SD) = 3.21 ± 0.41. Attitude score was assessed using Likert scale with a maximum of 5 to a minimum of 1, except items 1, 3,5, and 8 were assessed reversely. Scores were categorized using Bloom’s cut-off points: < 3 (< 59.0%) were considered negative attitude, 3–3.9 (60.0–79.0%) as neutral and 4–5 (80.0–100.0%) as a positive attitude toward Cranberry. Table 3Participants’ attitude toward Cranberry extracts (n = 409).Statementsn (%)Mean±SDStrongly agreeAgreeNeutralfStrongly disagree1. Cranberry extract is effective as a treatment option for recurrent urinary tract infection*222 (54.3)106 (25.9)43 (10.5)22 (5.4)16 (3.9)1.81.082. There is a difference between the pharmaceutical forms and herbs183 (44.7)151 (36.9)58 (14.2)11 (2.7)6 (1.5)4.20.893. Cranberry extract can replace the antibiotics in treatment of infections*48 (11.7)61 (14.9)72 (17.6)119 (29.1)109 (26.7)3.41.344. Pharmaceutical formulations are more beneficial than the crude herbal extract151 (36.9)113 (27.6)110 (26.9)28 (6.8)7 (1.7)3.91.035. Cranberry extract is safer than antibiotics for treatment of infections*128 (31.1)106 (25.9)113 (27.6)44 (10.8)18 (4.4)2.31.156. I believe that online selling of cranberry extract needs more monitoring211 (51.6)106 (25.9)66 (16.1)14 (3.4)12 (2.9)4.21.027. Cranberry extract is only effective as a prevention of recurrent urinary tract infection and not as a treatment option151 (36.9)122 (29.8)69 (16.9)53 (13.0)14 (3.4)3.81.168. In general, cranberry extracts are safe to be used frequently*155 (37.9)144 (35.2)83 (20.3)17 (4.2)10 (2.4)2.00.98MeanSDAttitude score**3.21± 0.41*These statements are reverse coded (Strongly disagree: 5, Disagree: 4, Neutral: 3, Agree: 2, Strongly agree: 1).**Attitude Score (mean ± SD) = 3.21 ± 0.41. Attitude score was assessed using Likert scale with a maximum of 5 to a minimum of 1, except items 1, 3,5, and 8 were assessed reversely. Scores were categorized using Bloom’s cut-off points: < 3 (< 59.0%) were considered negative attitude, 3–3.9 (60.0–79.0%) as neutral and 4–5 (80.0–100.0%) as a positive attitude toward Cranberry. Participants’ attitude toward Cranberry extracts (n = 409). *These statements are reverse coded (Strongly disagree: 5, Disagree: 4, Neutral: 3, Agree: 2, Strongly agree: 1). **Attitude Score (mean ± SD) = 3.21 ± 0.41. Attitude score was assessed using Likert scale with a maximum of 5 to a minimum of 1, except items 1, 3,5, and 8 were assessed reversely. Scores were categorized using Bloom’s cut-off points: < 3 (< 59.0%) were considered negative attitude, 3–3.9 (60.0–79.0%) as neutral and 4–5 (80.0–100.0%) as a positive attitude toward Cranberry. Among practice-section respondents (n = 268), ciprofloxacin was the most commonly reported antibiotic co-dispensed or associated with cranberry products (222/268, 82.8%), followed by cefuroxime/cefaclor (182/268, 67.9%), cefixime (130/268, 48.5%), and trimethoprim/sulfamethoxazole (128/268, 47.8%), Fig. 3. Fig. 3Antibiotics reported with cranberry co-dispensing among practice-section respondents (n = 268). Antibiotics reported with cranberry co-dispensing among practice-section respondents (n = 268). A total of 268/409 participants (65.5%) completed the practice-frequency section, whereas 141/409 (34.5%) did not provide complete practice responses. Among the 268 participants who completed the practice section, the mean practice score was 3.14 ± 0.70 out of 5. Most respondents reported that they always/often asked about chronic diseases (188/268, 70.1%) and chronic medications (184/268, 68.7%) before dispensing cranberry. However, potentially unsafe practices persisted: 148/268 (55.2%) reported always/often dispensing cranberry to pregnant or lactating patients, 122/268 (45.5%) reported always/often dispensing it regardless of age, 74/268 (27.6%) reported always/often dispensing it to patients with kidney stones, and 72/268 (26.9%) reported always/often dispensing it to patients using warfarin or aspirin (Table 4). Table 4Participants’ practice toward Cranberry extracts (n = 268).Statementsn (%)MeanSDAlwaysOftenSometimesRarelyNever1. I dispense cranberry extract supplement with a prescription only*62 (23.1)46 (17.2)90 (33.6)45 (16.8)25 (9.3)2.72± 1.252. I dispense cranberry extract supplement with prescribed urinary trat infection antibiotics*89 (33.2)93 (34.7)71 (26.5)10 (3.7)5 (1.9)2.06± 0.963. I dispense cranberry for patients who uses Warfarin or Aspirin*33 (12.3)39 (14.6)44 (16.4)44 (16.4)108 (40.3)3.58± 1.454. I dispense cranberry for patients with kidney stones*39 (14.6)35 (13.1)57 (21.3)47 (17.5)90 (33.6)3.43± 1.445. I am used to ask patients for their type of chronic medications before dispensing cranberry extract134 (50)50 (18.7)47 (17.5)20 (7.5)17 (6.3)3.99± 1.256. I dispense cranberry extract for all patients regardless of age*74 (27.6)48 (17.9)54 (20.1)45 (16.8)47 (17.5)2.79± 1.467. I dispense cranberry for patients who are Pregnant and lactating*85 (31.7)63 (23.5)50 (18.7)27 (10.1)43 (16.0)2.55± 1.438. I am used to ask patients for their chronic diseases before dispensing cranberry extract125 (46.6)63 (23.5)47 (17.5)18 (6.7)15 (5.6)3.99± 1.19*These statements are reverse coded (Never: 5, Rarely: 4, Sometimes: 3, Often: 2, Always: 1). Table 4Participants’ practice toward Cranberry extracts (n = 268).Statementsn (%)MeanSDAlwaysOftenSometimesRarelyNever1. I dispense cranberry extract supplement with a prescription only*62 (23.1)46 (17.2)90 (33.6)45 (16.8)25 (9.3)2.72± 1.252. I dispense cranberry extract supplement with prescribed urinary trat infection antibiotics*89 (33.2)93 (34.7)71 (26.5)10 (3.7)5 (1.9)2.06± 0.963. I dispense cranberry for patients who uses Warfarin or Aspirin*33 (12.3)39 (14.6)44 (16.4)44 (16.4)108 (40.3)3.58± 1.454. I dispense cranberry for patients with kidney stones*39 (14.6)35 (13.1)57 (21.3)47 (17.5)90 (33.6)3.43± 1.445. I am used to ask patients for their type of chronic medications before dispensing cranberry extract134 (50)50 (18.7)47 (17.5)20 (7.5)17 (6.3)3.99± 1.256. I dispense cranberry extract for all patients regardless of age*74 (27.6)48 (17.9)54 (20.1)45 (16.8)47 (17.5)2.79± 1.467. I dispense cranberry for patients who are Pregnant and lactating*85 (31.7)63 (23.5)50 (18.7)27 (10.1)43 (16.0)2.55± 1.438. I am used to ask patients for their chronic diseases before dispensing cranberry extract125 (46.6)63 (23.5)47 (17.5)18 (6.7)15 (5.6)3.99± 1.19*These statements are reverse coded (Never: 5, Rarely: 4, Sometimes: 3, Often: 2, Always: 1). Participants’ practice toward Cranberry extracts (n = 268). *These statements are reverse coded (Never: 5, Rarely: 4, Sometimes: 3, Often: 2, Always: 1). Inferential analyses Bivariate analyses showed that pharmacists working in community pharmacies had higher knowledge scores than other respondents (8.25 ± 2.64 vs. 6.99 ± 3.37; p < 0.001). Respondents who used research, books, or university-based sources also had higher knowledge scores (8.51 ± 2.69 vs. 7.36 ± 3.14; p < 0.001). Practice-section completers had higher knowledge scores than non-completers (8.14 ± 2.82 vs. 6.72 ± 3.32; p < 0.001). In multivariable linear regression, working in community pharmacy (β = 1.16, 95% CI 0.53 to 1.79; p < 0.001) and using research/books/university information sources (β = 1.18, 95% CI 0.43 to 1.92; p = 0.002) remained independent predictors of higher knowledge. In logistic regression, community pharmacy work (adjusted OR [aOR] = 0.60, 95% CI 0.39 to 0.92; p = 0.020) and research/books/university information sources (aOR = 0.52, 95% CI 0.31 to 0.87; p = 0.013) were associated with lower odds of low knowledge. Knowledge, attitude, and practice scores were positively but modestly correlated. Knowledge correlated with attitude (r = 0.107; p = 0.031) and practice (r = 0.227; p < 0.001), while attitude correlated with practice (r = 0.270; p < 0.001). Among practice-section respondents, higher knowledge (β = 0.05, 95% CI 0.02 to 0.08; p < 0.001), more positive attitudes (β = 0.44, 95% CI 0.26 to 0.63; p < 0.001), and postgraduate education (β = 0.51, 95% CI 0.28 to 0.74; p < 0.001) independently predicted safer practice scores, whereas > 5 years of experience was inversely associated with practice score (β=-0.24, 95% CI -0.48 to -0.005; p = 0.045) (Tables 5, 6). Table 5Summary of inferential analyses added in response to reviewer comments.AnalysisKey findingEstimatep valueBivariate knowledge scoreCommunity pharmacy vs. non-community8.25 ± 2.64 vs. 6.99 ± 3.37< 0.001Bivariate knowledge scoreResearch/books/university source vs. other sources8.51 ± 2.69 vs. 7.36 ± 3.14< 0.001Practice-section completion comparisonCompleters vs. non-completers knowledge score8.14 ± 2.82 vs. 6.72 ± 3.32< 0.001Linear regression: knowledge scoreCommunity pharmacyβ = 1.16 (95% CI 0.53 to 1.79)< 0.001Linear regression: knowledge scoreResearch/books/university sourceβ = 1.18 (95% CI 0.43 to 1.92)0.002Logistic regression: low knowledgeCommunity pharmacyaOR = 0.60 (95% CI 0.39 to 0.92)0.020Logistic regression: low knowledgeResearch/books/university sourceaOR = 0.52 (95% CI 0.31 to 0.87)0.013Practice score regressionKnowledge scoreβ = 0.05 (95% CI 0.02 to 0.08)< 0.001Practice score regressionAttitude scoreβ = 0.44 (95% CI 0.26 to 0.63)< 0.001Practice score regressionPostgraduate degreeβ = 0.51 (95% CI 0.28 to 0.74)< 0.001Practice score regressionExperience > 5 yearsβ=-0.24 (95% CI -0.48 to -0.005)0.045aOR, adjusted odds ratio; CI, confidence interval. Low knowledge was defined as < 60% of the total knowledge score ( < = 8/14). Higher practice scores indicate safer self-reported practice after reverse coding unsafe items. Table 5Summary of inferential analyses added in response to reviewer comments.AnalysisKey findingEstimatep valueBivariate knowledge scoreCommunity pharmacy vs. non-community8.25 ± 2.64 vs. 6.99 ± 3.37< 0.001Bivariate knowledge scoreResearch/books/university source vs. other sources8.51 ± 2.69 vs. 7.36 ± 3.14< 0.001Practice-section completion comparisonCompleters vs. non-completers knowledge score8.14 ± 2.82 vs. 6.72 ± 3.32< 0.001Linear regression: knowledge scoreCommunity pharmacyβ = 1.16 (95% CI 0.53 to 1.79)< 0.001Linear regression: knowledge scoreResearch/books/university sourceβ = 1.18 (95% CI 0.43 to 1.92)0.002Logistic regression: low knowledgeCommunity pharmacyaOR = 0.60 (95% CI 0.39 to 0.92)0.020Logistic regression: low knowledgeResearch/books/university sourceaOR = 0.52 (95% CI 0.31 to 0.87)0.013Practice score regressionKnowledge scoreβ = 0.05 (95% CI 0.02 to 0.08)< 0.001Practice score regressionAttitude scoreβ = 0.44 (95% CI 0.26 to 0.63)< 0.001Practice score regressionPostgraduate degreeβ = 0.51 (95% CI 0.28 to 0.74)< 0.001Practice score regressionExperience > 5 yearsβ=-0.24 (95% CI -0.48 to -0.005)0.045aOR, adjusted odds ratio; CI, confidence interval. Low knowledge was defined as < 60% of the total knowledge score ( < = 8/14). Higher practice scores indicate safer self-reported practice after reverse coding unsafe items. Summary of inferential analyses added in response to reviewer comments. aOR, adjusted odds ratio; CI, confidence interval. Low knowledge was defined as < 60% of the total knowledge score ( < = 8/14). Higher practice scores indicate safer self-reported practice after reverse coding unsafe items. Table 6Practice-section completion/non-response comparison.VariablePractice section completed (n = 268)Not completed (n = 141)p valueKnowledge score, mean ± SD8.14 ± 2.826.72 ± 3.32< 0.001Attitude score, mean ± SD3.19 ± 0.423.24 ± 0.400.241Community pharmacy, n (%)178/268 (66.4)37/141 (26.2)< 0.001Community/hospital sector, n (%)187/268 (69.8)44/141 (31.2)< 0.001Female, n (%)134/268 (50.0)73/141 (51.8)0.813Age > 35 years, n (%)50/268 (18.7)21/141 (14.9)0.414Postgraduate degree, n (%)28/268 (10.4)23/141 (16.3)0.121 Table 6Practice-section completion/non-response comparison.VariablePractice section completed (n = 268)Not completed (n = 141)p valueKnowledge score, mean ± SD8.14 ± 2.826.72 ± 3.32< 0.001Attitude score, mean ± SD3.19 ± 0.423.24 ± 0.400.241Community pharmacy, n (%)178/268 (66.4)37/141 (26.2)< 0.001Community/hospital sector, n (%)187/268 (69.8)44/141 (31.2)< 0.001Female, n (%)134/268 (50.0)73/141 (51.8)0.813Age > 35 years, n (%)50/268 (18.7)21/141 (14.9)0.414Postgraduate degree, n (%)28/268 (10.4)23/141 (16.3)0.121 Practice-section completion/non-response comparison. Discussion This study provides the first cranberry-specific assessment of pharmacists’ KAP in Jordan and now extends beyond descriptive reporting by examining predictors of knowledge, relationships among KAP domains, and the characteristics of participants who completed the practice section. Overall, the findings indicate moderate/neutral knowledge and attitudes, with important counselling gaps related to dose, interactions, kidney-stone risk, pregnancy/lactation uncertainty, and positioning cranberry as a preventive adjunct rather than a treatment substitute. The sample was balanced by gender but was skewed toward younger and early-career pharmacists and respondents from central Jordan. This pattern likely reflects the online, social-media-based recruitment strategy and may overrepresent digitally active pharmacists. Consequently, the findings may reflect early-career, digitally engaged pharmacists more than the full national pharmacy workforce. This limitation is particularly important because the main information source for many respondents was the internet and social media, whereas the inferential analysis showed that research/books/university-based sources independently predicted higher knowledge. The mean knowledge score (7.65 ± 3.07 out of 14) indicates moderate/neutral knowledge, while 57.9% of participants were classified as having low knowledge using Bloom’s < 60% cut-off. Working in a community pharmacy was associated with substantially better knowledge: in linear regression, community pharmacists scored about 1.2 points higher (on a 14-point scale) than others after adjustment, and in logistic regression, they had 40% lower odds of having low knowledge (aOR = 0.60) after controlling for covariates. Similarly, using research, books and university sources independently predicted higher knowledge scores and about 48% lower odds of low knowledge (aOR = 0.52). These complementary models show that both practice setting and the use of higher-quality information sources are not only correlated with mean scores but also meaningfully reduce the likelihood of falling below the 60% knowledge threshold. Studies from other contexts consistently find that structural and educational factors predict higher pharmacist knowledge and safer practice. In a study conducted in China to assess the knowledge, attitude and practice of pharmacists towards adverse drug reaction reporting, it was found that a higher education background, a higher professional title, attending training, and being a clinical pharmacist resulted in higher knowledge scores21. Similarly, working in an independent community pharmacy was found to be a factor linked with higher pharmacists’ knowledge regarding asthma management in Jordan22. Educational level, among other factors, was also found to be associated with higher knowledge towards COVIS-19 in a study conducted in Vietnam22. The positive association between evidence-based information sources and higher knowledge supports the need for structured continuing education and reliable supplement-counselling resources. This is consistent with the Jordanian study by Jalil et al., which reported concerns regarding community pharmacists’ awareness of herb–drug interactions and highlighted the need for evidence-based education on herbal medicines14. Additionally, Systematic reviews of pharmacist continuing education also emphasize that ongoing, high-quality learning activities are central to maintaining up-to-date knowledge23–25. A striking misconception emerged regarding cranberry’s oncological profile: 65.0% of pharmacists believed that cranberry supplementation increases cancer risk. This belief stands in direct contrast to extensive preclinical evidence demonstrating chemopreventive and antiproliferative effects of cranberry-derived proanthocyanidins, anthocyanins, and ursolic acid derivatives against multiple cancer types, including prostate, breast, colon, ovarian, and oral carcinomas through mechanisms such as cell-cycle arrest, apoptosis induction, and inhibition of angiogenesis and metastasis26. More than half of the participants correctly identified gastrointestinal disturbances and kidney stones as potential adverse effects. However, awareness of the specific mechanism, meaning cranberry-induced hyperoxaluria and elevated risk of calcium oxalate nephrolithiasis, was limited, with only 48% acknowledging this concern. Clinical data support this risk, showing significant increases in 24-hour urinary oxalate excretion (up to 43%) following regular consumption of cranberry tablets27. Fewer than half of respondents recognized cranberry’s possible suppressive effect on Helicobacter pylori. This finding should be interpreted cautiously: available evidence suggests a modest suppressive or adjunctive effect in some settings, but cranberry should not be presented as a substitute for standard H. pylori eradication therapy33. Pharmacists demonstrated inconsistent awareness of cranberry’s potential to potentiate anticoagulant and antiplatelet therapy. Numerous case reports and pharmacovigilance alerts have documented clinically significant interactions between high-dose cranberry juice (typically > 1 L/day) and warfarin, resulting in elevated international normalized ratios (INR) and serious bleeding episodes, primarily attributed to modest inhibition of CYP2C9 isoenzyme and possible S-warfarin accumulation28–30. Additionally, cranberry supplementation has been shown to exert an aspirin-like antiplatelet effect through non-enzymatic hydrolysis of proanthocyanidins and other polyphenols into salicylic acid derivatives31, leading to significantly elevated salicylic acid concentrations in plasma and urine after regular intake33. The limited recognition of possible anticoagulant/antiplatelet interactions and bleeding risk is clinically relevant. Only 46.2% recognized the bleeding-risk concern with excessive cranberry intake, and only 39.9% correctly rejected the statement that there is no anticoagulant interaction risk at moderate intakes. These findings support targeted education on herb–drug interaction screening, especially for patients using warfarin, direct oral anticoagulants, or antiplatelet therapy35–39. Similarly, the pregnancy/lactation item has been reinterpreted cautiously: safety remains uncertain due to limited evidence, and routine unsupervised use should not be recommended without clinical indication. This avoids the overly absolute implication that cranberry is proven unsafe at all doses. Despite the overall neutral attitude score (3.21 ± 0.4), different patterns for different items were observed. For instance, many of the pharmacists showed positive attitude agreeing that the pharmaceutical products are different than the crude herbal extract with extra monitoring is required for online selling of cranberry extract supplements. Despite that, less believe in the beneficial superiority of pharmaceutical formulation over the crude herbal extract. It is well recognised for consistent pharmacological and clinical outcomes, to standardize all known bioactive components in herbal products33. Furthermore, the neutral attitude was more obvious in admitting the role of cranberry in prevention rather than treatment of UTIs, and it is not an alternative for antibiotics treatment. Cranberry effect against urinary tract infection is mainly by inhibiting the adhesion of uropathogenic E. coli thus it has proven activity in preventing rather than treating UTIs34. Negative attitude score of (2.3 ± 1.15) was recorded for participants attitude towards the better safety profile of cranberry over antibiotics for treatment of infections, in other words 234 out of the 409 participants (57.2%) strongly agree or agree with the inaccurate perception of the superior safety of cranberry over antibiotics to treat infections. Moreover, 73.1% assume the frequent use of cranberry extract is safe in general, this demonstrates the profound negative attitude towards the safety of cranberry extract usage which is illustrated by the high safety expectation from the participants. It is worth to highlight that limited number of studies on the toxicities and side effects of using cranberry were conducted. Still few reports about herb drug interactions with warfarin [35] and tacrolimus36 were published. In addition cranberry extract can worsen the conditions of those taking proton pump inhibitors and histamine type 2 blockers by reducing their plasma concentration, besides its well-known GIT side effects37. Moreover, recent report blowed the whistle about the prolong exposure to high phenolic compounds with high doses, as in the case of high dosage cranberry intake might lead to histopathological changes mainly in kidney, liver and adipose tissue38. Among practice-section respondents, ciprofloxacin was the most commonly reported antibiotic used with cranberry products, followed by cefuroxime/cefaclor, cefixime, and trimethoprim/sulfamethoxazole. These data describe self-reported co-dispensing or preference patterns, not objectively verified prescriptions or evidence of appropriateness. Guideline recommends using cranberry as a preventive adjunct in selected UTI populations, but it should not delay diagnostic evaluation or replace clinically indicated antibiotics40,41. E. coli was found to be the main pathogenic organism in most of the UTIs cases in Jordan. Ciprofloxacin and trimethoprim/sulfamethoxazole were found to be the most prescribed in outpatient’s clinics according to a descriptive study conducted and lasted for 6 months in two major health institutions in two cities in Jordan42. Furthermore, a recent retrospective hospital data also report clinically relevant resistance among E. coli UTI isolates, underscoring the importance of stewardship and well-supported non-antibiotic options where appropriate43. Trimethoprim/sulfamethoxazole as the first line treatment for uncomplicated UTIs is suffering from high level of resistance, reaching around 70% according to a study conducted on population from Zarqa (second largest city in Jordan)43. In another study conducted in rural areas in Jordan trimethoprim/sulfamethoxazole resistance was around 47% and the resistance against ciprofloxacin was around 11%8. This might explain the high popularity of ciprofloxacin in expense of trimethoprim/sulfamethoxazole among our study group, which is showing agreement with the prescribing trend in Jordan. According to United States Pharmacopeial Convention and based on evaluation of different safety reports and data, consuming of less than 1350 mg/day of cranberry extract is considered safe44. Furthermore, A study was used in formulating the Cochrane review about cranberry found 1000 mg/ daily of a standardized cranberry product is safe45. Noteworthy, only 56% of the participants knew the safe dose for cranberry dietary supplement. Owing to the antiadhesion properties of proanthocyanidins in cranberry not only against those pathogens in urinary tract but also in other biological barriers, topical application of cranberry extract showed promising results in wound healing47. Natural components of cranberry extract were to improve hyperpigmentation when used topically47, even few reports indicate the potential for topical product with high content of cranberry proanthocyanidins in inhibiting the viral infection by herpes simplex type 1 and type 2 infections48. Interestingly, less than 43% of participants preferred the topical dosage form of cranberry extract, different factors can be attributed to this percentage such as the limited availability of topical cranberry pharmaceutical preparations, or mistrust of topical advantages which required more investigation and can be considered for future studies. The practice findings also require careful interpretation because only 268 participants completed the practice-frequency section. Respondents who completed the practice section had higher knowledge scores and were substantially more likely to work in community or hospital pharmacy. Therefore, practice results are most applicable to pharmacists involved in dispensing or counselling, and less applicable to pharmacists in academic, medical representative, or other non-dispensing roles. The positive independent associations of knowledge and attitude with safer practice support the conceptual KAP framework and provide a stronger analytical basis for targeted interventions. Limitations This study has several limitations. Recruitment relied primarily on social media and professional online networks, introducing self-selection bias and likely overrepresenting younger, early-career, digitally active pharmacists. The sample was also geographically skewed toward central Jordan, which limits national representativeness. The English questionnaire was justified by pharmacy education and professional reference use in Jordan, but English is not the native language of all respondents and may have contributed to item misinterpretation. The questionnaire was assessed for face/content validity and internal consistency, but construct validity was not formally established. “I do not know” responses were initially scored as incorrect for total knowledge calculation; however, the revised analysis reports them separately to distinguish uncertainty from misconceptions. Practice-related findings should also be interpreted cautiously. Only 268/409 respondents completed the practice-frequency section, and completion was associated with higher knowledge and community/hospital practice. Therefore, practice estimates may overrepresent pharmacists who encounter cranberry dispensing in routine work. In addition, some practice responses from pharmacists outside direct dispensing settings may represent perceived or hypothetical behaviour rather than actual observed practice. Future studies should use stratified random sampling across regions and practice sectors, collect product-level information, and validate counselling behaviour through observational or mixed-methods approaches. Clinical implication Clinical implications: These findings identify specific educational priorities for pharmacists in Jordan: differentiating prevention from treatment, avoiding claims that cranberry can replace antibiotics, screening for anticoagulant/antiplatelet therapy and kidney-stone risk, clarifying dose limits, and counselling carefully in pregnancy/lactation where evidence is limited. The inferential analyses suggest that improving access to evidence-based information sources and strengthening knowledge-attitude-practice links may improve counselling quality. Given the online recruitment and practice-section selection effects, these implications should be applied as targeted CPD priorities rather than as definitive national estimates of practice quality. Conclusion Jordanian pharmacists in this sample generally recognized cranberry’s preventive role in UTIs, but important gaps were observed regarding interactions, dose, kidney-stone risk, pregnancy/lactation uncertainty, and the distinction between prevention and treatment. Added inferential analyses showed that community-pharmacy work and evidence-based information sources independently predicted higher knowledge, while higher knowledge and more positive attitudes predicted safer self-reported practice among practice-section respondents. These findings support targeted continuing professional development on evidence-based cranberry counselling and herbal-supplement safety. However, conclusions should be interpreted cautiously because the online sample was young, centrally concentrated, and practice-section completion was not random.